secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2024-08-29T23:59:59+00:00
Accession:  0001193125-24-209907
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm CFO Michael Mason to resign Nov 5; transition agreement signed
-------------------------------------------------------------------------

- Michael Mason, EVP/CFO/Treasurer, notified resignation effective November 5, 2024; will serve until then.
- Company initiated search for a successor CFO.
- Transition agreement provides $100,000 lump sum payable on Nov 6, 2024, if employed through resignation.
- Mason to enter consulting agreement through March 1, 2025, with continued vesting of equity awards.
- Consulting fee: hourly pay after 5th hour each month; equity vesting continues during consultation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524209907/0001193125-24-209907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312524209907/d883504d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-209907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer